To compare the predictive performance of PSMB9 with previously reported immune response signatures [34,35], we analyzed the anti-PD-1 therapy data from a melanoma and a STAD cohort (PRJEB23709 and PRJEB25780) [25,26]. The gene discussed is PDCD1; the disease is melanoma.